Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Last Updated: September 27, 2022

Details for Patent: 7,516,741

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,516,741 protect, and when does it expire?

Patent 7,516,741 protects TOBI PODHALER and is included in one NDA.

Summary for Patent: 7,516,741
Title:Aerosolization apparatus with feedback mechanism
Abstract: An aerosolization apparatus comprises a housing defining a chamber having an air inlet and an air outlet, wherein the chamber is sized to receive a capsule containing a pharmaceutical formulation. A puncturing member is moveable within the chamber to contact the capsule and to provide an opening in the capsule, and a feedback mechanism provides an indication, such as a tactile indication, to a user when the puncturing member has been moved to a position where it provides the opening into the capsule. When air flows through the inlet, the pharmaceutical formulation is aerosolized and the aerosolized pharmaceutical formulation is delivered through the outlet.
Inventor(s): Glusker; Mark J. (San Mateo, CA), Wood; Jeff R. (Mountain View, CA), Burr; John D. (Redwood City, CA)
Assignee: Novartis AG (
Application Number:10/704,160
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,516,741
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Delivery; Device; Use; Process;

Drugs Protected by US Patent 7,516,741

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp TOBI PODHALER tobramycin POWDER;INHALATION 201688-001 Mar 22, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.